|
Pons-Fuster E, Martinez-Rodriguez R, Gimeno-Arias L, Alcaraz MJ, Moreno M, Gomez JM, Pelaez A, Garcia E, Tomas C, Munoz A, Martinez-Sanchez MV, Ruiz-Lorente I, Ceballos D, Minguela A, Bernal E. HLA-A*03 may confer protection against long COVID through an enhanced immune response. Infect Dis Now. 2025 Mar 17:105057. doi: 10.1016/j.idnow.2025.105057. Online ahead of print. PubMed PMID: 40107360.
AÑO: 2025; IF: 2.2
|
|
Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernandez-Avila JJ, Diaz-Carrasco MS, Espuny-Miro A. Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. Int J Clin Pharm. 2025 May 6. doi: 10.1007/s11096-025-01920-4. Online ahead of print. PubMed PMID: 40327314.
AÑO: 2025; IF: 3.2
|
|
López-Jornet P., Hynninen J.N., Parra-Perez F., Peres-Rubio C., Pons-Fuster E., Tvarijonaviciute A. The Role of Salivary Biomarkers in Monitoring Oral Health in Patients with Implants and Periodontitis. Applied Sciences (Switzerland). January 2024. 14. 10.3390/app14020927
AÑO: 2024; IF: 2.5
|